Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ACRO BIOMEDICAL CO., LTD.

Get SEC filing alerts via email and in your feed for ACRO BIOMEDICAL CO., LTD.

ACBM

ACRO BIOMEDICAL CO., LTD.

About ACRO BIOMEDICAL CO., LTD.

Acro Biomedical Co., Ltd. is a nutritional products company focused on promoting wellness through cordyceps-based offerings, primarily targeting markets in Taiwan and Hong Kong. Despite past sales, the company has faced significant challenges, including a lack of revenue since 2022 and halted product development. Acro aims to explore new opportunities, including a proposed cordyceps-infused chicken feed, while navigating a competitive landscape and regulatory hurdles.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from ACRO BIOMEDICAL CO., LTD.

1
1
ACRO BIOMEDICAL CO., LTD. ACRO Biomedical Reports Continued Revenue Decline and Increased Net Loss in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
ACRO BIOMEDICAL CO., LTD. Acro Biomedical Reports No Revenue and Significant Losses in 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
ACRO BIOMEDICAL CO., LTD. ACRO Biomedical Reports No Revenue and Increased Losses in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
ACRO BIOMEDICAL CO., LTD. ACRO Biomedical Reports No Revenue for Q2 2025, Increases Losses and Operating Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
ACRO BIOMEDICAL CO., LTD. Acro Biomedical Reports $10,301 Net Loss and No Revenue in Q1 2025

Via official filing (AI summary) | 11 months ago | 0 comments

6
1
ACRO BIOMEDICAL CO., LTD. Acro Biomedical Reports No Revenue and $42,297 Net Loss in 2024 Filing

Via official filing (AI summary) | 11 months ago | 0 comments

7
1
ACRO BIOMEDICAL CO., LTD. ACRO Biomedical Reports No Revenue for Q3 2024, Continues Financial Losses

Via official filing (AI summary) | 11 months ago | 0 comments

8
1
ACRO BIOMEDICAL CO., LTD. ACRO Biomedical Reports No Revenue and Significant Losses in Q2 and First Half of 2024

Via official filing (AI summary) | 11 months ago | 0 comments

9
1
ACRO BIOMEDICAL CO., LTD. ACRO Biomedical Reports $11,252 Net Loss in Q1 2024, No Revenue Generated

Via official filing (AI summary) | 11 months ago | 0 comments

10
1
ACRO BIOMEDICAL CO., LTD. Acro Biomedical Reports No Revenue and $8.8 Million Loss in 2023

Via official filing (AI summary) | 11 months ago | 0 comments

11
1
ACRO BIOMEDICAL CO., LTD. ACRO Biomedical Reports No Revenue for Q3 2023, Faces Financial Challenges

Via official filing (AI summary) | 11 months ago | 0 comments